IL144084D0 - Therapeutic calcium phosphate particles and methods of manufacture and use - Google Patents

Therapeutic calcium phosphate particles and methods of manufacture and use

Info

Publication number
IL144084D0
IL144084D0 IL14408400A IL14408400A IL144084D0 IL 144084 D0 IL144084 D0 IL 144084D0 IL 14408400 A IL14408400 A IL 14408400A IL 14408400 A IL14408400 A IL 14408400A IL 144084 D0 IL144084 D0 IL 144084D0
Authority
IL
Israel
Prior art keywords
nm
methods
calcium phosphate
biologically active
core particles
Prior art date
Application number
IL14408400A
Original Assignee
Biosante Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11836499P priority Critical
Priority to US11835699P priority
Priority to US11835599P priority
Application filed by Biosante Pharmaceuticals Inc filed Critical Biosante Pharmaceuticals Inc
Priority to PCT/US2000/002742 priority patent/WO2000046147A2/en
Publication of IL144084D0 publication Critical patent/IL144084D0/en

Links

Abstract

Novel calcium phosphate core particles, methods of making them, and methods of using them as vaccine adjuvants, as cores, as carriers of biologically active material, and as controlled release matrices for biologically active material are disclosed. The core particles may have a surface modifying agent and/or biologically active material, such as antigenic material or natural immunoenhancing factor, polynucleotide material, or therapeutic proteins or peptides, partially coating the particle or impregnated therein. The core particles have a diameter between about 300 nm and about 4000 nm, more particularly between about 300 nm and about 2000 nm, and even more particularly between about 300 nm and about 1000 nm, are substantially spherical in shape, and have a substantially smooth surface
IL14408400A 1999-02-03 2000-02-03 Therapeutic calcium phosphate particles and methods of manufacture and use IL144084D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11836499P true 1999-02-03 1999-02-03
US11835699P true 1999-02-03 1999-02-03
US11835599P true 1999-02-03 1999-02-03
PCT/US2000/002742 WO2000046147A2 (en) 1999-02-03 2000-02-03 Therapeutic calcium phosphate particles and methods of manufacture and use

Publications (1)

Publication Number Publication Date
IL144084D0 true IL144084D0 (en) 2002-05-23

Family

ID=27382150

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14408400A IL144084D0 (en) 1999-02-03 2000-02-03 Therapeutic calcium phosphate particles and methods of manufacture and use
IL144084A IL144084A (en) 1999-02-03 2001-07-01 Therapeutic calcium phosphate particles and methods of manufacture and use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL144084A IL144084A (en) 1999-02-03 2001-07-01 Therapeutic calcium phosphate particles and methods of manufacture and use

Country Status (12)

Country Link
US (4) US6355271B1 (en)
EP (1) EP1150918B1 (en)
AT (1) AT276199T (en)
AU (1) AU2753100A (en)
CA (1) CA2361421A1 (en)
DE (1) DE60013773T2 (en)
DK (1) DK1150918T3 (en)
ES (1) ES2228467T3 (en)
IL (2) IL144084D0 (en)
MX (1) MXPA01007895A (en)
PT (1) PT1150918E (en)
WO (1) WO2000046147A2 (en)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2285430C (en) 1997-04-01 2008-11-18 Cap Biotechnology, Inc. Calcium phosphate microcarriers and microspheres
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US20020068090A1 (en) * 1999-02-03 2002-06-06 Bell Steve J. D. Calcium phosphate particles as mucosal adjuvants
IL144084D0 (en) 1999-02-03 2002-05-23 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
WO2006073503A1 (en) * 2001-02-27 2006-07-13 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles for use in inhibiting expression of a gene
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
GB9910975D0 (en) * 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
DE60041971D1 (en) 1999-07-08 2009-05-20 Cap Biotechnology Inc Calcium-containing STRUKTURE and process of making and using thereof
DE10028975B4 (en) * 2000-06-16 2005-06-30 Henkel Kgaa Compositions for treating tooth and / or bone tissue
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US20020192137A1 (en) * 2001-04-30 2002-12-19 Benjamin Chaloner-Gill Phosphate powder compositions and methods for forming particles with complex anions
GB0116074D0 (en) * 2001-06-29 2001-08-22 Univ Strathclyde Nanoparticle structures
IN192520B (en) * 2001-08-01 2004-04-24 Univ Delhi A process of preparing entrapping genetic materials in nanoparticles of inorganic metal salts
ES2405405T3 (en) 2001-12-17 2013-05-31 Corixa Corporation Compositions and methods for therapy and diagnosis of inflammatory bowel disease
US8097270B2 (en) 2001-12-21 2012-01-17 Novartis Ag Use of nanoparticles as carriers for biocides in ophthalmic compositions
DE60237475D1 (en) 2001-12-21 2010-10-07 Alcon Inc Use of synthetic inorganic nanoparticles as carriers for ophthalmic drug
MXPA04010282A (en) * 2002-04-18 2005-08-18 Acuity Pharmaceuticals Inc Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye.
WO2004006929A1 (en) * 2002-07-11 2004-01-22 Taiho Pharmaceutical Co., Ltd. Composition for nasal absorption
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004065546A2 (en) 2003-01-16 2004-08-05 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ICAM-1
AU2004262640B2 (en) 2003-06-16 2010-12-23 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
GB0324897D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
NZ546379A (en) * 2003-10-31 2010-04-30 Teva Pharma Nanoparticles for drug delivery
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
AU2005219372A1 (en) 2004-02-13 2005-09-15 Safeway Investments Ltd. Therapeutic calcium phosphate particles and methods of making and using same
EP1811941A4 (en) 2004-11-01 2008-09-10 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles iin use for aesthetic or cosmetic medicine, and methods of manufacture and use
DE602005023509D1 (en) 2004-11-16 2010-10-21 3M Innovative Properties Co Dental fillers, methods, compositions with a caseinate
EP1819313B1 (en) * 2004-11-16 2010-12-29 3M Innovative Properties Company Dental fillers and compositions including phosphate salts
EP2535355B1 (en) 2005-03-23 2019-01-02 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
FR2887457B1 (en) * 2005-06-23 2007-10-05 Fond Bettencourt Schueller Transcutaneous immunization by targeting
JP4948806B2 (en) 2005-08-09 2012-06-06 Hoya株式会社 Method for producing particles
CN101365494A (en) * 2005-10-05 2009-02-11 贝希尔治疗学股份有限公司 Compositions and methods for treatment of autoimmune disease
US20090035326A1 (en) * 2005-11-01 2009-02-05 Novartis Ag Compositions with antigens adsorbed to calcium phosphate
ES2377884T3 (en) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Flu vaccines that include combinations of particulate adjuvants and immunopotentiating
EP2368572A3 (en) 2005-11-04 2013-04-24 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ568429A (en) * 2005-12-07 2012-04-27 Nycomed Pharma As Film-coated and/or granulated calcium-containing compounds and use thereof in pharmaceutical compositions
EP1976559B1 (en) 2006-01-27 2017-01-04 Novartis Influenza Vaccines Marburg GmbH Influenza vaccines containing hemagglutinin and matrix proteins
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
WO2007126825A2 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
WO2007133758A1 (en) * 2006-05-15 2007-11-22 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
WO2009030978A2 (en) 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
ES2390499T3 (en) * 2006-06-12 2012-11-13 Opko Pharmaceuticals, Llc Compositions and methods for inhibiting angiogenesis sirna
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2662473A1 (en) * 2006-09-06 2008-03-13 Boston Scientific Limited Medical devices having nanostructured coating for macromolecule delivery
WO2008030557A2 (en) * 2006-09-08 2008-03-13 Johns Hopkins University Compositions and methods for enhancing transport through mucus
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US20100010199A1 (en) 2006-09-11 2010-01-14 Novartis Ag Making influenza virus vaccines without using eggs
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US20080241256A1 (en) * 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
ES2393162T3 (en) 2007-06-27 2012-12-19 Novartis Ag influenza vaccines with a reduced additive content
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2222697B1 (en) 2007-11-01 2012-12-05 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
US20100260849A1 (en) * 2007-12-13 2010-10-14 Rusin Richard P Remineralizing compositions and methods
GB0724498D0 (en) * 2007-12-15 2008-01-30 Univ Strathclyde Slow release compositions
EP2235532B1 (en) 2007-12-24 2013-04-24 Novartis AG Assays for adsorbed influenza vaccines
TWI346666B (en) * 2007-12-31 2011-08-11 Animal Technology Inst Taiwan Method for seperating casein from casein-contained solution
EP2077273B1 (en) 2007-12-31 2011-09-14 Animal Technology Institute Taiwan Methods for separating casein from soluble proteins in a composition
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
EP2889042A3 (en) 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
WO2009135190A2 (en) 2008-05-01 2009-11-05 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
CN102076784A (en) * 2008-05-08 2011-05-25 3M创新有限公司 Surface-modified nanoparticles
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2361306A1 (en) 2008-12-04 2011-08-31 OPKO Ophthalmics, LLC Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
UA109633C2 (en) 2008-12-09 2015-09-25 An antibody against human tissue factor
US8790707B2 (en) * 2008-12-11 2014-07-29 3M Innovative Properties Company Surface-treated calcium phosphate particles suitable for oral care and dental compositions
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
CA2754691A1 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
JP5830009B2 (en) 2009-04-14 2015-12-09 ノバルティス アーゲー Composition for immunizing against Staphylococcusaureus
DE102010018462A1 (en) 2009-04-27 2011-04-07 Novartis Ag Vaccines to protect against influenza
US8574589B2 (en) 2009-05-11 2013-11-05 Novartis Ag Antigen purification process for pertactin antigen
JP2012532600A (en) 2009-07-07 2012-12-20 ノバルティス アーゲー Stored E. coli immunogen
SG178026A1 (en) 2009-07-15 2012-03-29 Novartis Ag Rsv f protein compositions and methods for making same
EP2464658B1 (en) 2009-07-16 2014-10-01 Novartis AG Detoxified escherichia coli immunogens
US9937128B2 (en) 2009-08-03 2018-04-10 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
US20120164232A1 (en) * 2009-09-09 2012-06-28 Tokyo Institute Of Technology Construct coated with virus coat-constituting protein and method for producing same
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
JP2013512677A (en) * 2009-12-04 2013-04-18 オプコ オプサルミクス、エルエルシー Compositions and methods for inhibition of Vegf
ES2707778T3 (en) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Immunogens polysaccharides conjugated with carrier proteins of E. coli
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
CA2791278C (en) 2010-02-25 2015-11-24 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
CN107739407A (en) 2010-03-10 2018-02-27 根马布股份公司 Monoclonal antibodies against c-MEt
CN107253992A (en) 2010-05-27 2017-10-17 根马布股份公司 Monoclonal antibodies against her2
CN103796677A (en) 2011-04-20 2014-05-14 根马布股份公司 Bispecific antibodies against HER2 and CD3
JP6177231B2 (en) 2011-04-20 2017-08-09 ゲンマブ エー/エス Her2 for the bispecific antibody
CA2800769A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2 epitope
US9249226B2 (en) 2010-06-09 2016-02-02 Genmab A/S Antibodies against human CD38
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
CN106084053A (en) 2010-06-15 2016-11-09 根马布股份公司 Human Antibody Drug Conjugates Against Tissue Factor
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
CN103228273B (en) 2010-09-29 2017-04-05 普马特里克斯营业公司 Monovalent metal cations dry inhalation powder
CA2812417A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
SI2667892T1 (en) 2011-01-26 2019-05-31 Glaxosmithkline Biologicals Sa Rsv immunization regimen
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
AU2012255971A1 (en) 2011-05-13 2013-05-02 Novartis Ag Pre-fusion RSV F antigens
EP2723365A1 (en) 2011-06-21 2014-04-30 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab B V Dimeric protein with triple mutations
JP6088507B2 (en) 2011-07-08 2017-03-01 ノバルティス アーゲー The method of tyrosine ligation
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
RU2472471C1 (en) * 2011-11-24 2013-01-20 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения и социального развития Российской Федерации Method of reducing intraocular pressure
US20150044251A1 (en) 2011-12-23 2015-02-12 Novartis Ag Stable compositions for immunising against staphylococcus aureus
WO2013138343A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
JP6138904B2 (en) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー Non linear multi-block copolymers drug conjugates for the delivery of active agent
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256130B2 (en) 2012-05-03 2017-12-21 Johns Hopkins University, The Pharmaceutical nanoparticles showing improved mucosal transport
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
CA2915575A1 (en) 2013-07-05 2015-01-08 Genmab A/S Humanized or chimeric cd3 antibodies
JP6435261B2 (en) 2012-08-31 2018-12-05 ノバルティス アーゲー Proteins stabilized for immunization against Staphylococcusaureus
WO2014033191A1 (en) 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
TR201808684T4 (en) 2012-10-02 2018-07-23 Glaxosmithkline Biologicals Sa Non-linear saccharide conjugates.
KR20150073943A (en) 2012-10-03 2015-07-01 글락소스미스클라인 바이오로지칼즈 에스.에이. Immunogenic composition
WO2014064710A1 (en) 2012-10-22 2014-05-01 Department Of Biotechnology A process for the prepartion of non-viral vector for delivery of nucleic acids by mucosal route
RS56886B1 (en) 2012-11-30 2018-04-30 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CA2900652A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
BR112015020139A2 (en) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compounds and therapeutic uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA2907566A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
AU2013401479B2 (en) 2013-09-26 2019-04-04 Biontech Rna Pharmaceuticals Gmbh Particles comprising a shell with RNA
CN108530458A (en) 2013-11-01 2018-09-14 卡拉制药公司 Crystalline forms of therapeutic compounds and uses thereof
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
US10132818B2 (en) 2014-07-08 2018-11-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
US20180326084A1 (en) 2015-07-10 2018-11-15 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
CN107074948A (en) 2014-07-11 2017-08-18 根马布股份公司 Antibodies binding AXL
ES2557183B1 (en) * 2014-07-21 2016-11-03 Consejo Superior De Investigaciones Científicas (Csic) Process for obtaining nanoparticles coated amorphous calcium phosphate and citrate fluorine-doped
TW201716436A (en) 2015-07-13 2017-05-16 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
CA3027561A1 (en) 2016-07-12 2018-01-18 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau and methods of use thereof
SG11201811431VA (en) 2016-07-14 2019-01-30 Genmab As Multispecific antibodies against cd40 and cd137
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
RU2657780C2 (en) * 2016-09-14 2018-06-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Agent for treatment of eye diseases and method of its use
CA3046977A1 (en) * 2016-12-16 2018-06-21 Delphi Scientific, Llc Layered particles and processes thereof
BR112018016717A2 (en) 2016-12-16 2018-12-26 H Lundbeck As agents, uses and methods
BR112018067721A2 (en) 2017-01-04 2019-01-08 H Lundbeck As hyperphosphorylated tau specific antibodies for the treatment of eye diseases
WO2018162749A1 (en) 2017-03-09 2018-09-13 Genmab A/S Antibodies against pd-l1
WO2018178396A1 (en) 2017-03-31 2018-10-04 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
WO2018224609A1 (en) 2017-06-07 2018-12-13 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
US20190023788A1 (en) 2017-07-20 2019-01-24 H. Lundbeck A/S Agents, uses and methods for treatment
WO2019025545A1 (en) 2017-08-04 2019-02-07 Genmab A/S Binding agents binding to pd-l1 and cd137 and use thereof

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3183545A (en) 1961-06-29 1965-05-18 Bergstrom Eric Victor Easy slide caster
AU407324B2 (en) 1962-05-01 1970-10-28
US4016252A (en) 1972-04-06 1977-04-05 Institut Pasteur Calcium phosphate gel for adsorbing vaccines
FR2181426B1 (en) 1972-04-06 1974-12-20 Pasteur Institut
US4075321A (en) * 1973-05-04 1978-02-21 Agence Nationale De Valorisation De La Recherche (Anvar) Vaccines, the process for preparing the same and the applications thereof
FR2227861B1 (en) * 1973-05-04 1976-07-02 Anvar
FR2466991B1 (en) 1979-10-08 1982-10-15 Pasteur Institut
FR2505657B1 (en) 1981-05-13 1984-03-30 Pasteur Institut
FR2522269B1 (en) * 1982-02-26 1985-03-01 Pasteur Institut
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
FR2577048B1 (en) * 1985-02-05 1988-05-06 Pasteur Institut Reagent for the determination by haemagglutination of antibodies against bacterial toxins, process for the preparation and application
US4683202B1 (en) * 1985-03-28 1990-11-27 Cetus Corp
US4683195B1 (en) * 1986-01-30 1990-11-27 Cetus Corp
CA1291036C (en) 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
US4983341A (en) * 1987-12-28 1991-01-08 United Technologies Corporation Method of using breather materials for high pressure molding
IL88961A (en) 1988-01-29 1992-07-15 Basf Ag Stable mixtures containing oxidation-sensitive compounds
US5428066A (en) 1989-03-08 1995-06-27 Larner; Joseph Method of reducing elevated blood sugar in humans
CA2357538A1 (en) 1989-03-21 1990-10-04 Wisconsin Alumni Research Foundation Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5219577A (en) 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
US5306508A (en) 1990-06-22 1994-04-26 The Regents Of The University Of California Red blood cell surrogate
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5460830A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Biochemically active agents for chemical catalysis and cell receptor activation
US5441739A (en) 1990-06-22 1995-08-15 The Regents Of The University Of California Reduced and controlled surface binding of biologically active molecules
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5462751A (en) 1990-06-22 1995-10-31 The Regeants Of The University Of California Biological and pharmaceutical agents having a nanomeric biodegradable core
US5464634A (en) 1990-06-22 1995-11-07 The Regents Of The University Of California Red blood cell surrogate
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery
US5462634A (en) * 1991-08-23 1995-10-31 Honda Giken Kogyo Kabushiki Kaisha Surface-treated aluminum material and method for its surface treatment
US6537574B1 (en) 1992-02-11 2003-03-25 Bioform, Inc. Soft tissue augmentation material
DE69333556D1 (en) 1992-02-28 2004-07-22 Cohesion Tech Inc Injektierbare ceramic compounds and processes for their preparation and use
US5204382A (en) 1992-02-28 1993-04-20 Collagen Corporation Injectable ceramic compositions and methods for their preparation and use
PT584348E (en) 1992-03-11 2005-10-31 Powderject Vaccines Inc Genetic vaccine for immunodeficiency virus
US5620896A (en) 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
DE69332536T2 (en) * 1992-09-30 2003-09-04 Tdk Corp Magnetic recording medium
FR2698560B1 (en) 1992-11-30 1995-02-03 Virbac Laboratoires Principles stabilized powdery active, compositions containing them, process for their preparation and their applications.
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5456986A (en) 1993-06-30 1995-10-10 Carnegie Mellon University Magnetic metal or metal carbide nanoparticles and a process for forming same
US5469599A (en) * 1993-10-27 1995-11-28 Wurdack; Roy A. Slide
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
IL113817A (en) 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
DK0702085T4 (en) * 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Recombinant infectious non-segmented negative-strand RNA virus
CA2172373C (en) * 1994-08-30 1999-03-16 Bhagwati P. Kabra Thermally-gelling ophthalmic drug delivery vehicles containing cellulose ethers
CA2199005A1 (en) * 1994-09-01 1996-03-07 Serge Petit Compositions and methods for delivery of polypeptides
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5789229A (en) * 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
DE4444052A1 (en) 1994-12-10 1996-06-13 Rhone Poulenc Rorer Gmbh Pharmaceutical, oral preparation
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US8333996B2 (en) 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
US5676976A (en) 1995-05-19 1997-10-14 Etex Corporation Synthesis of reactive amorphous calcium phosphates
US6541037B1 (en) 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US6579516B1 (en) * 1995-06-13 2003-06-17 Zahra Mansouri Methods of delivering materials into the skin, and compositions used therein
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US6264957B1 (en) * 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US5695617A (en) 1995-11-22 1997-12-09 Dow Corning Corporation Silicon nanoparticles
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
US5985312A (en) * 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
JPH09205491A (en) 1996-01-26 1997-08-05 Nec Telecom Syst Ltd Isdn telemetering system
GB9602797D0 (en) 1996-02-12 1996-04-10 Unilever Plc Inorganic material in particles form
US5827822A (en) 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
JPH10114897A (en) 1996-10-11 1998-05-06 Sangi Co Ltd Powdery perfume, preparation thereof and use thereof
WO1998020389A1 (en) * 1996-11-08 1998-05-14 Optical Coating Laboratory, Inc. Coated flexible glass films for visual display units
CA2280839A1 (en) * 1997-02-14 1998-08-20 Merck & Co., Inc. Polynucleotide vaccine formulations
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
CA2285430C (en) * 1997-04-01 2008-11-18 Cap Biotechnology, Inc. Calcium phosphate microcarriers and microspheres
US5891420A (en) 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
AU3860797A (en) 1997-07-16 1999-02-10 Antrin Research Limited Pharmaceutical formulations for oral administration
US6187335B1 (en) 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
US6017545A (en) 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6251474B1 (en) * 1998-11-06 2001-06-26 Idaho Research Foundation Method of producing substantially spherical magneto-plumbite ferrite particles
WO2006073503A1 (en) 2001-02-27 2006-07-13 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles for use in inhibiting expression of a gene
US20020054914A1 (en) 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
IL144084D0 (en) 1999-02-03 2002-05-23 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use
US20020068090A1 (en) 1999-02-03 2002-06-06 Bell Steve J. D. Calcium phosphate particles as mucosal adjuvants
US20040258763A1 (en) 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US20030185892A1 (en) 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
US6183803B1 (en) 1999-06-11 2001-02-06 Biosante Pharmaceuticals, Inc. Method for processing milk
US6183335B1 (en) * 1999-12-10 2001-02-06 Christine Petersen Suspended display arrangement for vehicles
JP2001302431A (en) 2000-04-21 2001-10-31 Mitsui Chemicals Inc Cosmetic containing calcium phosphate fine-grain
AU2003288902A1 (en) 2002-09-06 2004-04-08 Genteric, Inc. Microcapsules and methods of use

Also Published As

Publication number Publication date
AT276199T (en) 2004-10-15
DK1150918T3 (en) 2004-12-20
AU2753100A (en) 2000-08-25
US6355271B1 (en) 2002-03-12
IL144084A (en) 2006-10-31
WO2000046147A2 (en) 2000-08-10
PT1150918E (en) 2005-01-31
WO2000046147A3 (en) 2000-12-07
US20010048925A1 (en) 2001-12-06
EP1150918B1 (en) 2004-09-15
US20110236685A1 (en) 2011-09-29
ES2228467T3 (en) 2005-04-16
EP1150918A2 (en) 2001-11-07
US20070292454A1 (en) 2007-12-20
DE60013773T2 (en) 2005-11-10
CA2361421A1 (en) 2000-08-10
DE60013773D1 (en) 2004-10-21
MXPA01007895A (en) 2003-07-21
US8431221B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
TWI288644B (en) New liquid pharmaceutical composition comprising unpegylated erythropoietin protein and preparation process thereof
AU670759B2 (en) In situ use of gelatine or an amino dextran in the preparation of uniform ferrite particles
TW557217B (en) Pharmaceutical dry powder compositions for use in treating respiratory disorders and the process for preparing the same
TW380053B (en) An improved solid dosage form of the type comprising a porous network of matrix material that disperses rapidly in water
TWI290577B (en) Wiring-connecting material and wiring-connected board production process using the same
TW476638B (en) Method of marking a breathable absorbent article and breathable absorbent article obtained therefrom
TW505528B (en) Free-flowing dried particles
PL345115A1 (en) Slow release of fragrant compounds in perfumery using 2-benzoyl benzoates, 2-alkanoyl benzoates or &agr;-keto esters
NZ530123A (en) Particles comprising DPPC, insulin, sodium citrate and optionally an amino acid in a composition for inhalation that has rapid release properties
CA2496611A1 (en) Agent delivery particle
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
UA65538C2 (en) Ultrafine dry powder compositions of biological macromolecules, methods for their preparation and application
IL111628A (en) Synthetic membrane vesicles with controlled release of encapsulated biologically active substances, process for their preparation and a targeted delivery system comprising them
MY118835A (en) Sustained release compositions and the process for their preparation
CA2014889A1 (en) Intra-rectal pharmaceutical foam compositions
CA2293575A1 (en) Controlled release microencapsulated ngf formulation
AU7815594A (en) Dental prosthesis with composite support shell and coating, preimpregnated fabric part, manufacturing method and machine
UA72206C2 (en) Coated chewing gum, method of obtaining thereof and using one or several active ingredients in solid form
AU5341696A (en) Biologically active peptides and compositions, their use
CA2395709A1 (en) Process for the preparation of micronised collagen, and its therapeutic applications
CA2223269A1 (en) Hepatocyte growth factor receptor antagonists and uses thereof
IL116454D0 (en) Process for the preparation of powders for inhalation and powders obtainable thereby
MXPA96004911A (en) Sustained-release matrix pellets and method for preparing them.
CA2171303A1 (en) Active principles and gas containing microparticles
CA2235919A1 (en) Non-polymeric sustained release delivery system

Legal Events

Date Code Title Description
FF Patents granted
KB Patents renewed
KB Patents renewed